Category Archives: Transhuman News

One of the most elusive aspects for clinicians treating COVID-19 is the bodys immune response to the virus. In the most severe cases of COVID-19, the immune system goes into overdrive, resulting in a fever, multiorgan system damage, and often deatha cytokine storm. But how to detect and treat a cytokine storm requires that clinicians can identify it as such.

Two Penn Medicine researchers have developed a unifying definition of cytokine storm to provide physicians with a framework to assess and treat severely-ill patients whose immune systems have gone rogue. Cytokine storms can be triggered by different pathogens, disorders, or treatments, from COVID-19 to Castleman disease to CAR T cell therapy.

In a paper published in the New England Journal of Medicine, David Fajgenbaum, an assistant professor of translational medicine & human genetics and director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), and Carl June, a professor of pathology and laboratory medicine and director of the Center for Cellular Immunotherapies in the Abramson Cancer Center, and the Parker Institute for Cancer Immunotherapies define a cytokine storm as requiring elevated circulating cytokine levels, acute systemic inflammatory symptoms, and secondary organ dysfunction beyond what could be attributed to a normal response to a pathogen, if a pathogen is present.

There has never been a defining central review of what a cytokine storm is and how to treat one, and now with COVID-19, that is a major issue, says Fajgenbaum, a Castleman disease patient who has previously experienced five cytokine storms himself. Ive spent the last 10 years of my life as a cytokine storm patient and researcher, so I know the importance of having a comprehensive unified definition to find therapies that work across the various types of cytokine storms.

There is widespread recognition that the immune response to a pathogen, but not the pathogen itself, can contribute to multiorgan dysfunction and other symptoms. Additionally, similar cytokine storm syndromes can occur with no obvious infection.

Read more at Penn Medicine News.

See more here:
Charting a path forward with unifying definition of cytokine storm - Penn Today

CL20046574Jat Sikh family of Physicians invite match for their beautiful daughter Canadian born 31, 5'-7", DMD in Dental Practice in USA. Well versed in both cultures. Please respond with details and recent picture to: jjsingh1471@gmail.com

CL20047866Canada based well educated Jat Sikh parents invite matrimonial alliance for their Canadian citizen daughter, convent educated, very fair, beautiful, sober, cultured, family-oriented, 30, 5'-6", BBA having permanent job with Provincial Government. Boys should be handsome, professionally qualified and belong to a respectable Jat Sikh family. Please send bio-data and pictures at: matrimon597@gmail.com or WhatsApp: 778-939-9393.

CL20063689UK citizen Khatri Hindu Punjabi parents seeking a match for their UK born Pharmacists daughter, 39, 5'-3", legally divorced, issueless. Vegetarian, slim, fair complexion. purshtommatri9@btinternet.com

CL20063984Suitable match for Brahmin slim, fair, good looking girl, 29/ 5'-3", B.Tech., MBA, working MNC Bangalore, 18 LPA. Contact 9465130303, 9321652851.

CL20065217Reputed Jatt Sikh business family seeks professionally qualified well settled match for their November 87 born, (5'-4"), beautiful, slim, cultured and highly qualified daughter (Ph.D in Human Genetics from prestigious University). Whatsapp: 9988051888.

CL20065793Suitable match for professionally qualified Jatt Sikh beautiful, slim girl US Citizen born in Oct '87 and height 5'-5". She Graduated with Masters in Public Health, Biostatistics. Currently she is working as Quantiative Research Analyst with well- renowned Hospital Research Institution in Northern California. We are well settled family in the US for the past 35 years. Please contact with biodata and recent pictures: lakhmann60@gmail.com

CL20067396Wanted well qualified Gursikh match for Jatt Sikh Canadian PR girl Chandigarh educated 87 born, 5'-5", LL.M. Contact 79734-75173.

CL20068155Match for beautiful Jat Sikh girl, 1991, 165 convent educated B.Tech Computer Science working as Grade-1 in Nationalized bank. Malwa preferred. E-mail: bti1980@yahoo.com

CL20068705Looking for suitable match for convent educated Jat Sikh girl, Dec. 1993 born, 5'-2", B.Com., PGDCA. Currently working in Canada, PR applied. Good family background. Send bio-data and photographs at: zsingh0419@gmail.com. Canada/USA preferred.

CL20068723Slim, fair, smart 1988 born, 5'-6", Convent educated Sikh Ahluwalia girl, B.Tech Computer Science, UIET, (Chandigarh), PGDM, S.P. Jain(Mumbai), Shortly joining MNC with package around 30 Lacs per annum, working in IT, family settled in Chandigarh. Cut-surd / caste / religion no bar. Send biodata and photos on Whatsapp: 75084-54385.

CL20068725Professionally qualified match for USA PR August 1990, 5'-8", Jalandhar born beautiful Saraswat Brahmin B.Tech girl. Send biodata with recent photograph. Contact: 98760-95174.

CL20068772Match for beautiful Canadian PR, well settled Hindu Punjabi girl, BBA (Canadian University), 29.03.1993, 10:10 pm (Chandigarh), 5'-2". Whatsapp: +919041931993, 9814016463. Email: mvbhatia154@gmail.com

CL20068855Suitable match for girl, 5'-4", 27.04.1991, 9:55 a.m. Chandigarh, Manglik, B.Tech. Computer Engineer, working Gurgaon, package above 9.50 lakh. Contact: 95017-26775.

CL20068917Suitable match for 1990 born, Jatt Sikh girl, 5'-6", fair, smart, MBA, working in MNC. Seeks well educated boy preferred in job in India. Contact: 70149-24971.

CL20068987Seeking well settled handsome alliance for Punjabi Hindu khatri girl from well connected family, 28/5'-7, beautiful, fair, slim, talented, fluent in English, BDS, employed in MNC. Good prospects in pharmaceutical, biotechnology and IT sector. Caste not rigid. Mobile: 86992-79692.

CL20069016Match for Brahmin beautiful girl 07 May. 1994, 09:54 am, Panchkula, 5'-3", M.Sc. Maths, B.Ed., CTET clear, working in Private School, Chandigarh. Tricity and Pinjore are preferred. Contact: 94633-90330.

CL20069088Seeking suitable well settled match for slim, beautiful Tonk Kashtriya girl, 26.02.1985, 5-1, MA English, B.Ed. NRI welcome. Early marriage. Upper caste no bar. Brother Doctor. Father Engineer. Well settled family. Whatsapp: +919855555189

CL20069104Well educated settled for Hindu Convent educated single girl, 5'-1", 1994, BE, environment job. Preferred Tricity. 97794-56638, amit11chd@gmail.com

CL20069132Retired Class-I Officer Mohali settled seeking suitable match for slim, beautiful girl 87 born/5'-4", M.A. English. Proposal from fair, tall boy from respectable Sikh family preferably NRI/Govt Officer. E-mail: singhjaspreet90001@gmail.com

CL20069157PQM4 Mair Rajput 85, MS, 5 feet. H1B visa, Canada PR. Currently India. 9915949434 Email: mtrymny@gmail.com

CL20069352Professionally qualified match for Canada PR Sikh Tonk-Kashtriya beautiful girl 36 yrs, 5'-2". MCA with distinction, working in reputed IT Company as Tech lead, handsome package, Issueless divorcee, educated family. Brother and sister in USA. Issueless or unmarried preferred. Upper caste welcome. Please contact: +919417199243. Email: hari.singh2227086@gmail.com

CL20069431SM4 slim fair 24, 5'-4", BA, MJMC Mohali based Sikh girl, WhatsApp only. 94635-78500.

CL20069443Suitable match for vegetarian beautiful Arora working girl, 5'-2",1986, MBA (HR). Father Govt. Officer, Mohali. Tricity working preferred. Contact: 94176-80409. 83601-95093. Email: dk69monga@gmail.com

CL20069446Wanted NRI Indian match for Jangra Brahmin girl, Haryana Hisar family, M.Sc Maths, pursuing Ph.D final year. Whatsapp detail to 78218-05544, 93160-30909.

CL20069656Chandigarh based status Jat Sikh family invites alliance for their intelligent, smart and beautiful daughter, 84/5'-6". Masters from Ivy League University and Doctorate from USA. Doctor, Engineer or highly qualified professional match. Greencard in process. Send biodata and photos whatsapp at 98557-43279. Email : pirthisinghdhaliwal@gmail.com

CL20069682SMF Tall fair and beautiful, 5'-7" Mahajan girl, 1992, Convent educated, M.Tech Gold Medalist, presently Govt. Lecturer, Canada PR under process, prefer tall boy, highly qualified well settled abroad. 97795-86770. Email: mahajan_1962@yahoo.co.in

CL20069842Match for beautiful Canadian educated Post-graduate Computer Science Engineer Punjabi Rajput girl, working as IT Analyst in Canada, 25 yrs, 5'-1". No bars. Canadian preferred. E-mail: saritarana78922@gmail.com

CL20069910Required Doctor/Engineer/NRI unmarried/divorcee (issueless) below 36 for Hindu Prajapati slim, fair, 5'-1", 1987, BDS, divorcee (short marriage) girl. Parents retired officer. Upper caste welcome. 9417859277, 9417658577.

CL20070033Medico/Non-medico professional Arora/Khatri match from US/Canada for Canadian PR August 84 born (never married) beautiful Punjabi girl. 5'-3". M.D (Gynae), registered Sonographer Canada & US. Whatsapp: 9417113114.

CL20070240Suitable match for Ramgarhia girl, Senior Research Fellow, 1992 born, 5"-4', pursuing PHD. Calligrapher. Well settled family at Mohali. Tricity preferred. 94173-01016.

CL20070548Match for Australian PR, Doaba based Ramdasia Sikh girl, 31 yrs, 5'-2", M.Sc. Food Technology. Father retired Xen. Send biodata whatsapp: 8360311712.

CL20070606Match for 1993 born/ 5'-3" Sikh Ramgarhia girl, doing her Masters in Australia, persons with Australian Citizenship PR will be preferred. Contact: 98775-28315, 62838-68430.

CL20070789Professionally qualified match for fair Punjabi Saraswat Brahmin girl, 1984/5'-1", M.Sc., B.Ed., Govt regular Teacher (TGT) in Delhi. Mail: scsharma.05@gmail.com 98993-83246.

CL20070871Match for Pbi. Manglik Brahmin girl, working in a Govt. Bank as P.O. 28.08.1992, 10.44 pm, Patiala. Contact: 70872-30576.

CL20070920Professionally qualified match for beautiful Jat Sikh girl, 5'-3", 14 August 1994, Chemical Engineer, MBA, PU, Chandigarh. Working MNC, Asstt. Manager. Father Bank Manager (Retd.). Mother Govt. School Teacher. Whatsapp: 79867-93884, 79867-83074.

CL20070947SM for Saraswat Brahmin M.Com.,UGC- NET girl, 5'-4", 29.01.1990, 3:35 pm, Chandigarh. Working as Lecturer in a reputed school in Chandigarh. Gotra- Dwivedi and Prashar. Originally belong to near Nangal, Punjab. Settled in Chandigarh. Contact: 98729-68811.

CL20070955Suitable match for Nai Sikh girl 25, 5'-1", B.Tech., working as Software Engineer at Mohali. Boy should be well-settled. NRI/ Software Engineer preferred. Contact: 98153-40925.

CL20070960Suitable match for Gupta girl, Nov. 1982 (B.Tech+ MBA), working MNC, decent well educated family. Upper caste no bar. 95969-78787, arungupta7272@gmail.com

CL20071010Suitable match for Brahmin girl, May 1984, Ayurvedic Doctor BAMS-MD, Yoga expert and professor in Medical College. Well settled family. Seeking professionally well qualified vegetarian, Brahmin boy preferably North Indian Origin, 98193-29649, send biodata and latest photographs on sonikasudan@gmail.com

Read the original post:
Grooms Wanted - The Tribune

A causal relationship between high density lipoprotein cholesterol (HDL-C) and gout was established in a Mendelian randomization study published in the Journal of Human Genetics.

Genetic data and HDL-C, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglyceride (TG) concentrations from 110,347 individuals of European ancestry included in the Global Lipids Genetics Consortium were examined in relation to a gout diagnosis (n=69,374) using additive regression adjusted for covariates.

A significant relationship between HDL-C and gout was observed: for every 12.26 mg/dL increase in HDL-C, the odds of having gout were decreased (odds ratio [OR], 0.75; 95% CI, 0.62-0.91; P =3.3110-3).

To further examine the relationship between HDL-C and gout, the investigators employed a leave-one-out approach to test the contribution of 92 instrumental HDL-C variables. The 2 largest effects were observed for the gene Aldehyde Dehydrogenase 1 Family Member A2 (ALDH1A2) and microRNA AC012181.1. The effect sizes of these 2 variables were low and did not affect the association between HDL-C and gout (OR, 0.74; 95% CI, 0.60-0.91; P =4.1810-3).

Concentrations of other lipids did not significantly alter odds of having gout. For every 30.25 mg/dL increase in LDL-C, the OR for gout was 0.81 (95% CI, 0.61-1.07; P =.079). A 36.32 mg/dL increase in TC was associated with an OR for gout of 0.98 (95% CI, 0.90-1.06; P =.604) and a 112.33 mg/dL increase in TG was associated with an OR of 1.16 for gout (95% CI, 0.93-1.45; P =.186).

Serum urate was negatively associated with HDL-C (estimated causal effect, -0.09; 95% CI, -0.12 to -0.05; P =7.0010-4) and positively associated with TG (estimated causal effect, 0.10; 95% CI, 0.06-0.14; P =9.8710-5).

Using a mediation analysis, the total effect of HDL-C on gout was -0.154 (95% CI, -0.256 to -0.051; P =3.3110-3), the direct effect was -0.106 (95% CI, -0.189 to -0.022; P =1.3510-2), and the mediation effect was -0.020 (95% CI, -0.033 to -0.008; P =1.6710-3). The mediation effect accounted for 13.0% of the total variance, indicating that urate may be an important mediator of gout and HDL-C.

In the mediation analysis, TG had a similar but inverse relationship, in which the total effect on gout was 0.082 (95% CI, -0.039 to 0.202; P =1.8610-1), the direct effect was 0.048 (95% CI, -0.057 to 0.152; P =3.71101), and the mediation effect was 0.023 (95% CI, 0.0100.037; P =8.39104). This mediation effect of urate on gout accounted for 28.0% of the total variance.

This study was limited by its sample size. Although the study included tens of thousands of adults with gout, the cases only represented 3.1% of the total dataset, possibly limiting the study power.

These data confirmed the causal association between HDL-C and TG with gout and found that serum urate levels likely mediate these relationships.

Reference

Yu X, Wang T, Huang S, et al. Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis. [published online October 25, 2020] J Hum Genet. doi:10.1038/s10038-020-00863-0

See original here:
Causal Association Between HDL-C, TG and Gout Identified - The Cardiology Advisor

THOUSAND OAKS, Calif., Dec. 3,2020 /PRNewswire/ --Amgen (NASDAQ:AMGN) will host a webcast call for the investment community on Tuesday, Dec. 8, at 4:00 p.m. ET following the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of the clinical development team, will participate to discuss our oncology and hematology programs with a focus on Amgen's innovative BiTE platform including the first clinical data for AMG 701 and analyses from a BLINCYTO (blinatumomab) Phase 3 pediatric study.

Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, http://www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to beone ofthe world'sleadingindependent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visitwww.amgen.comand follow us onwww.twitter.com/amgen.

CONTACT: Amgen, Thousand OaksMegan Fox, 805-447-1423 (media)Trish Rowland, 805-447-5631(media)Arvind Sood, 805-447-1060 (investors)

SOURCE Amgen

Read more:
Amgen To Webcast Investor Call At ASH 2020 - PRNewswire

SOUTH PLAINFIELD, N.J., Dec. 4, 2020 /PRNewswire/ --PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that Translarna (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD). It is estimated that 13% of DMD patients have a nonsense mutation. In countries where it is approved, Translarna is currently the only medicine that targets the underlying cause of nmDMD.1

"Translarna was the first therapeutic ever approved for nonsense mutation Duchenne muscular dystrophy patients and we are excited to expand approval of Translarna into Russia," stated Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, Inc. "There has been great interest from Russian physicians to be able to access a treatment that targets the underlying cause of the disease, and a number of nmDMD patients have already been identified who can potentially benefit from Translarna. Our goal is to bring this product to nmDMD patients globally and this approval marks another important milestone."

Translarna marketing approval has been granted by the Ministry of Health of the Russian Federation for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense mutation in patients 2 years and older. Primarily affecting males, DMD is a rare, irreversible, and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure.2 It is caused by the lack of functional dystrophin protein.2

About TranslarnaTranslarna (ataluren), discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged two years and older. Translarna is being distributed in over 50 countries. Ataluren is an investigational new drug in the United States.

About PTC Therapeutics, Inc.PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at http://www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.

For More Information:

InvestorsLisa Hayes+1 (732) 354-8687lhayes@ptcbio.com

Media:Jane Baj+1 (908) 912-9167jbaj@ptcbio.com

Forward-Looking Statements:This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the commercialization of its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; PTC's ability to complete a dystrophin study necessary to support a re-submission of its Translarna NDA for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) to the FDA, and PTC's ability to perform any necessary additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

1Birnkrant DJ, et al. Lancet Neurol. 2018;17:251267. Kalman L, et al. J Mol Diagn. 2011;13:167174. Bladen CL, et al. Hum Mutat. 2015;36:395402. Pichavant C, et al. Mol Ther. 2011;19:830840. Prior, et al. American Journal of Human Genetics 1995.

2About Duchenne. (n.d.). Retrieved November 30, 2020, from https://takeonduchenne.co.uk/about-duchenne/

View original content:http://www.prnewswire.com/news-releases/ptc-announces-translarna-approval-in-russia-for-the-treatment-of-duchenne-muscular-dystrophy-301186438.html

SOURCE PTC Therapeutics, Inc.

Read this article:
PTC Announces Translarna Approval in Russia for the Treatment of Duchenne Muscular Dystrophy - BioSpace

Abstract

Although somatic mutations in Histone 3.3 (H3.3) are well-studied drivers of oncogenesis, the role of germline mutations remains unreported. We analyze 46 patients bearing de novo germline mutations in histone 3 family 3A (H3F3A) or H3F3B with progressive neurologic dysfunction and congenital anomalies without malignancies. Molecular modeling of all 37 variants demonstrated clear disruptions in interactions with DNA, other histones, and histone chaperone proteins. Patient histone posttranslational modifications (PTMs) analysis revealed notably aberrant local PTM patterns distinct from the somatic lysine mutations that cause global PTM dysregulation. RNA sequencing on patient cells demonstrated up-regulated gene expression related to mitosis and cell division, and cellular assays confirmed an increased proliferative capacity. A zebrafish model showed craniofacial anomalies and a defect in Foxd3-derived glia. These data suggest that the mechanism of germline mutations are distinct from cancer-associated somatic histone mutations but may converge on control of cell proliferation.

The study of histones and their role in epigenetics is a rapidly expanding field. Histones are nuclear proteins that associate with DNA to facilitate packaging into condensed chromatin. Histones are dynamically decorated with posttranslational modifications (PTMs), which regulate these processes as DNA repair, gene expression, mitosis, and meiosis. Dysregulation of PTMs leads to cancer, neurodevelopmental syndromes, psychiatric disorders, and even cardiovascular disease (14). The vast array of diseases that stem from histone dysregulation makes understanding histone biology vital to understanding the pathophysiology of many diseases and developing treatments. Histones are highly evolutionarily conserved, and only a few germline disease-causing variants in the histones themselves have been found (5). Rather, most disease-causing variants affecting histone regulation are found in histone-modifying proteins or histone chaperones. Somatic mutations in histone H3.3 (H3.3), encoded by both H3F3A and H3F3B, have recently been identified in pediatric glia and other tumors. This discovery revolutionized the field of epigenetic changes in tumors and how they lead to cancer progression (6). There has been one case report suggesting a relationship between a neurodevelopmental syndrome and H3F3A, but no additional patients or functional data have been published previously (7). Studying how histone mutations cause disease can provide the key to understanding how mutations in the histone network lead to disease.

Histone 3 family 3 (H3F3) histones (H3.3) mark active genes, maintain epigenetic memory, and maintain heterochromatin and telomeric integrity. Every nucleosome contains a version of H3. H3.1 and H3.2 are canonical histones that are replication dependent and, therefore, added to chromatin only during DNA replication. H3.3, however, is a replication-independent variant, which differs from the canonical H3.1 and H3.2 by only five and four amino acids, respectively (8). H3F3A and H3F3B code for an identical protein product, H3.3, a 135amino acid protein (after cleavage of the first methionine) with a histone tail, four helices, and two loop domains. These genes, however, contain different regulatory and coding sequences, which lead to different expression patterns and levels for H3F3A and H3F3B. Both H3F3B and H3F3A are expressed ubiquitously, during development and throughout life, with relatively high levels of expression in the brain, testes, ovaries, and uterus (9).

Because of the biologic importance of H3F3A and H3F3B, their orthologs have been studied extensively in multiple model organisms. When both H3f3a and H3f3b are knocked out in mice, it causes embryonic lethality at embryonic day 6.5, and reduced expression leads to sterility, growth retardation, and increased neonatal lethality (10). Disrupting either His3.3A or His3.3B in Drosophila is tolerated; however, disrupting both leads to sterility and increased lethality (11). While knockout models have been studied in mice and Drosophila, germline missense mutations have not. There have been many studies in yeast that show the lethality of various missense mutations, but it is difficult to infer whether that means missense mutations in humans would also have a profound effect (12).

In this work, we have identified a cohort of 46 unrelated patients bearing de novo heterozygous germline missense mutations in H3F3A or H3F3B with a core phenotype of progressive neurologic dysfunction and congenital anomalies. Notably, although all known H3.3 mutations in humans cause cancer, none of the patients in our cohort have cancer. These mutations are distinct and appear to be acting, although it is a completely different pathogenic mechanism than the cancer-causing mutations. The mutations are spread throughout the coding sequence, and neither the location of the mutation nor whether the mutation is in H3F3A or H3F3B appears to affect the phenotype. The breadth of these previously unidentified disease-causing mutations in H3F3A and H3F3B provides evidence for how sensitive the neural-related functions of H3.3 are to small variation.

Our patient cohort consists of 46 unrelated patients bearing de novo germline missense mutations in H3F3A or H3F3B (Fig. 1). Both H3F3A and H3F3B code for H3.3. Therefore, a heterozygous mutation in either gene would affect only about 25% of the total H3.3 in the cell, depending on different expression levels from the two genes. None of the patients have malignancies, but they share a phenotype of developmental delay, usually severe and often progressive, with mostly minor congenital anomalies (Table 1). These patients were identified through exome or genome sequencing performed for the indication of neurodevelopmental delays and/or congenital anomalies (Table 1, fig. S1, and table S1). There is substantial phenotypic heterogeneity in the patients, and future individuals are likely to be identified using unbiased molecular testing. Notably, 9 of the 46 patients (21%) have demonstrated clinical neurologic degeneration, which suggests that this may be a progressive disorder. Multiple patients (26% of the cohort) have cortical atrophy on brain magnetic resonance imaging (MRI), even without intractable epilepsy. For example, the oldest patient in this cohort (32 years) developed seizures at the age of 14 years and a progressive spastic paraparesis starting at the age of 29 years.

N, 1, 2, and 3 refer to the N-Helix, Helix-1, Helix-2, and Helix-3 of H3.3, respectively. Upper mutations are encoded by H3F3B, and lower mutations are encoded by H3F3A. Red arrows indicate mutations found in two or more unrelated patients. A few variants, p.N108S, p.P121R, and p.Q125R, were found in the same position in both H3F3A and H3F3B. *p.S146X is only present in an H3F3B alternate transcript not shown here.

Developmental delay was seen in varying degrees in the majority of patients; hypotonia, poor growth, oculomotor abnormalities, seizures, abnormal skull shape, and microcephaly were also commonly seen in the patients.

The severity of the phenotype does not correlate with the location of the mutation or whether the mutation is in H3F3A or H3F3B. Four unrelated patients have the p.T45I mutation and exhibit the full range of the phenotype severity. The age at sitting for patients with the p.T45I mutation ranges from 8 months to not achieved within 4.5 years. The age at walking was 21 months, 2 years, and 3 years and not achieved at 4.5 years. One exhibited developmental regression, while the other three did not, and only one has seizures. Even the tone abnormalities are inconsistent with three exhibiting hypotonia, while one has hypertonia. This strongly suggests that the variation in phenotype is not due to the location of the mutation but rather due to either modifying alleles or environmental factors.

Five mutations [H3F3A (NM_002107.4) p.R17G, p.T45I, p.A114G, p.Q125R, and H3F3B (NM_005324.4) p.P121R] were detected in two or more unrelated patients. p.Q125R was found in H3F3A in three individuals and in a different individual in H3F3B, while p.P121R was found in H3F3A in one individual and in H3F3B in two other individuals. Notably, in two patients, the mutations (H3F3A p.Q125R and p.V117L) were identified only by trio genome sequencing after negative exome sequencing, as the last exon of H3F3A is currently not covered by some exome capture kits. We speculate that similar mutations in H3F3A may be underdiagnosed in current exome studies. It should be noted for nomenclature consistency purposes that, historically, many publications on H3.3 exclude the initiator methionine in the residue count. In this publication, we will use the traditional histone nomenclature and exclude the first methionine. However, we will include traditional human genetics nomenclature in the clinical table of mutations and include this first residue in the mutation notation.

One mutation in H3F3B (p.S146X) is only present in the alternate transcript. It is p.V117V in the canonical transcript. Although the mutation is only in the alternate transcript, the patient phenotype is consistent with the rest of the cohort, and the patient cells have the same phenotype as the other patient cells analyzed. The role of the alternate transcript is currently unknown and requires additional study.

These 37 unique missense mutations in 46 patients are all de novo and, with one exception (H3F3A c.362 T > A; p.M120K, 1 incidence), are not found in a large database of 138,632 controls, the Genome Aggregation Database (gnomAD) (13). Upon closer view of the raw data for this p.M120K variant, it may be a technical mapping error, as it is only present on one strand and did not meet the previous Exome Aggregation Consortium (ExAC) quality control criteria for reporting. In the general population, both genes have a very low rate of missense variants; the gnomAD missense Z score is 3.21 for H3F3A and 2.95 for H3F3B (>2 is significant) (13).

It is likely that these variants are pathogenic through various different mechanisms, as they are found throughout the entire coding sequence in different domains. To explore these mechanisms further, we used molecular modeling of all 37 of the variants reported here. These 37 variants were mapped to a total of 25 loci distributed over several experimental structures. Eleven locations were in the structure of H3.3 in the nucleosome; at the sequence level, they spread from central positions to near the C-terminal end of H3.3. The remaining 14 locations (as well as H39, which was also present in the nucleosome) were mapped to different complexes between H3.3 and epigenetic regulators. At the sequence level, they concentrated in the N-terminal tail of H3.3.

In Fig. 2 (top), we show the location of the variants in the H3.3 structure (for clarity, they are shown only in one H3.3 monomer) and (Fig. 2, bottom) a summary of the amount and type of interatomic contacts at each mutation locus. Together, these data suggest three broad scenarios for the variants impact. In the first one, variants are likely to disrupt the H3.3-DNA interaction because the native residue is involved in a large number of contacts with the DNA. For instance, this would be the case of p.R83C because the arginine residue penetrates the DNA minor groove. In the second scenario, variants are more likely to disrupt the histone octamer, either because they affect the intramonomer contacts of H3.3 (e.g., p.Q125R) or because they may alter the interaction of H3.3 with other nucleosomal histones (e.g., p.L48R). In the third scenario, the variants disrupt histone-protein binding such as the p.G90R mutation disrupting chaperone binding. In summary, through different mechanisms, the variants in this section are likely to affect the formation, the deposition, or the stability of the nucleosomes containing H3.3 or of the nucleosome pairing. This may result in a generalized loosening of chromatin structure in those processes requiring the incorporation of H3.3 to the nucleosome.

At the top of the figure, we show the structure of the nucleosome with the H3.3 variants identified with spheres; the H3.3 monomer carrying them is colored in dark emerald green. The coloring of the variants reflects the predominating interactions at each location: DNA binding (magenta), intramonomer contacts (light orange), and contacts with other histones (dark blue). The same color code is used in the histogram below the structure, where we show the amount of the three interaction types at each location. Note that we use different y axis for these interactions: The y axis to the left corresponds to the H3.3-DNA binding contacts (magenta bars), and the y axis to the right corresponds to the intramonomer (light orange bars) and intermonomer contacts (dark blue bars).

The available complexes between H3.3 and epigenetic regulators (Fig. 3A) involve short stretches of the H3.3 tail bound to sites of different shapes (Fig. 3B). The number of interprotein contacts at the variant locus may vary substantially. For example, p.H39 has 33 and 4 contacts with SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) and ZMYND11 (Zinc Finger MYND-Type Containing 11) domains, respectively. We find that residues p.R8, p.S31, p.K36, and p.H39 are involved in more than 10 contacts across epigenetic regulators, suggesting that their mutation may disrupt one or more biologically relevant interactions. For the remaining residues, the number of interprotein contacts decreases rapidly, limiting our ability to interpret mutation impact. For example, visual analysis of the H3.3-BRD4 (Bromodomain-containing protein 4) complex shows that p.A15 barely participates in the complex between both proteins; contact analysis shows that p.A15 has only one interatomic contact with Brd4. Consequently, we conclude that destabilization of the H3.3-Brd4 complex is an unlikely explanation for pathogenic variants. A general mechanism that may also be valid for variants in the histone tail is that they may disrupt the internucleosome packing, an important interaction in which H3 tails are involved (14). In summary, most of the variants in this section are likely to affect the interaction between H3.3 and epigenetic regulators with consequences that will depend on the biological role of each complex, or they may loosen chromatin structure by disrupting internucleosome packing.

Variant locations could be mapped to the experimental structure of different complexes involving H3.3. In (A), we show the variants mapped and the gene names of the H3.3 partners in the corresponding complex. The same color is used for the lines originating in the same variant These complexes include CARM1 (Coactivator Associated Arginine Methyltransferase 1), ZMYND11, SETD2, NSD3 (Histone-lysine N-methyltransferase NSD3), MORC3 (MORC Family CW-Type Zinc Finger 3), MLLT3 (MLLT3 Super Elongation Complex Subunit), KDM1B (Lysine Demethylase 1B), and BRD4. In (B), we show the total amount of interatomic interactions at each location, for each H3.3-epigenetic regulator complex. To help interpretation, we give three examples where we can see the histone tail (blue spheres) interacting with its partner (continuous surface in light orange); the histone residue at the variant location is shown in magenta.

To quantify this histone PTM dysregulation, patients Epstein-Barr virustransformed lymphoblasts (H3F3A p.A15G, H3F3A p.R17G, H3F3A p.T45I, H3F3B p.A29P, and H3F3B p.P121R) and primary fibroblasts (H3F3A p.R17G, H3F3A p.G90R, and H3F3A p.T45I) were obtained from patients and age- and ethnicity-matched controls. Histones were extracted and analyzed by nanoliquid chromatographytandem mass spectrometry (LC-MS/MS) as previously described (15). This allowed for a rigorous and robust quantification of histone PTM levels, providing insight into the global epigenetic state in each cell type. For reference, the average of the control lymphoblasts is depicted in Fig. 4A. Notably, analysis of coefficients of variation both within and across patients and controls revealed that the distribution of histone PTM abundances was very similar (Fig. 4B). Although these data show modest changes compared to cells that express p.K27M- or p.K36M-mutant H3.3, which display a near complete loss of di- and trimethylation at K27 or K36, a dominant negative effect cannot be ruled out (16).

(A) Average profile of PTMs on canonical histones H3 and H4 across control lymphoblasts. Error bars represent SD (n = 9 donors; 3 biological replicates each). (B) Tukey boxplot depicting the coefficients of variation of 73 modified histone H3 and H4 peptides detected by nanoLC-MS/MS (biological variance: across all 14 donors; patient variance: across five patients; control variance: across nine controls). (C) Average histone H3.3 protein abundance (relative to total histone H3) in patient and control lymphoblasts. Error bars represent SD. (D) Volcano plot demonstrating significantly altered histone PTMs in patients versus controls. Dotted line represents P < 0.05 significance threshold. (E) K9 and K14 PTM abundances were compared between (i) protein transcribed from the mutant p.A15G allele from patient cells, (ii) protein transcript from the wild-type (WT) allele from the same patient cells, and (iii) protein transcribed from the WT alleles from a control. Note that the peptide from amino acids 9 to 17 is indistinguishable between canonical H3 and H3.3, so the WT peptide encompasses both. (F) A29P is the only mutation occurring on the same peptide that distinguishes H3.3 from H3. PTMs that fall on this peptide are compared across the mutant peptide, the WT peptide from the mutant sample, and the average profile of the peptide from control samples. *P < 0.05, **P < 0.01, and ***P < 0.001. This shows notable local deregulation of PTMs on the mutant peptide. qMS, quantitative mass spectrometry.

It was also observed that the overall histone PTM variation was slightly greater in healthy donors than in patients. Nonetheless, some histone PTMs were reproducibly altered when comparing patients to controls (Fig. 4D). Although all patients share a common phenotype of developmental delay, only some of them developed major congenital malformations (i.e., cardiac and cranial anomalies). Further study of the specific local dysregulation during development may lead to insights into the transcriptional control in these processes (i.e., cardiac and cranial development). In general, the magnitude of the changes was modest and may reflect the cell types studied and developmental timing.

The tails of H3.3 and the other H3 histones (1 to 89 amino acids) are identical except for residue 31, where they contain alanine and serine, respectively. Because peptides are generated by cleavage at arginine residues, it is technically impossible to assign PTMs to a specific H3 histone, except in the case of p.A29P. For this case, two PTM abundances (K27 and K36) were compared between (i) protein transcribed from the mutant p.A29P allele from patient cells, (ii) protein transcript from the wild-type (WT) allele from the same patient cells, and (iii) protein transcribed from the two WT alleles from a control (Fig. 4E). These data show notable local deregulation of PTMs on the mutant protein, while the WT protein from the affected patient shows fewer differences from the control. This is a more minor effect than that of published somatic oncogenic mutations; however, the difference neither confirms nor refutes a dominant negative effect (17).

Together, these data suggest that the mutant histones can be incorporated into the nucleosome, cause marked local deregulation of chromatin state, and modestly alter the global control of histone modifications. Of greatest interest are the local chromatin changes induced by mutant histone deposition: H3.3 is known to have roles in diverse functions, including gene expression and repression, chromatin stability, DNA damage repair, and differentiation. These mutant proteins and their aberrant PTM states could disrupt any of these processes to lead to the observed phenotype.

To evaluate which biological pathways were differentially perturbed in the patients, we performed RNA sequencing (RNA-seq) on fibroblast cells derived from patients and age- and ethnic-matched controls. All reads were aligned with the STAR (Spliced Transcript Alignment to a Reference) aligner, and Cufflinks was used for performing differential expression analysis. In fibroblast cells (three mutations listed above versus three controls), the H3.3 transcripts (H3F3A and H3F3B) contribution to total histone H3 expression ranged from 45.1 to 72.6% in cases and 64.1 to 81.7% in controls (table S2). We found 323 genes to be differentially expressed with at least two fold changes in fibroblast cells (P < 0.05; table S3). Of these 323 genes, 166 were up-regulated, and 157 were down-regulated in cases. Differentially expressed genes were analyzed through David Functional Annotation Resource, and we found no significant biological signal in the genes with lower expression in cases but showed significant enrichment for up-regulated genes important in mitotic cell cycle process [Benjamini-Hochbergcorrected P (PBH-corrected) = 7.8 1014], mitotic nuclear division (PBH-corrected = 5.8 1010), cell division (PBH-corrected = 7.5 1010), and many other mitosis-related processes (table S4).

To assess whether up-regulation of mitosis-related genes alters cells proliferation, we quantified the cellular proliferation capacity of five patient fibroblast lines compared to six age- and sex-matched control fibroblast lines. Patient lines had increased cell proliferation, notably at 72 and 96 hours (Fig. 5A). Furthermore, all five patient lines shared similar viability to the six control lines (Fig. 5B). Cell cycle analyses showed that H3F3A p.G90R and H3F3A p.T45I had a similar cell cycle profile to the control lines, while H3F3A p.R17G showed a decrease in cells in G1 phase and an increase in cells in S phase compared to all three control lines (Fig. 5C).

(A) Five H3F3A/B patient fibroblast lines (H3F3B: p.G34V; H3F3A: p.R17G; H3F3A: p.G90R; H3F3A: p.T45I; and H3F3B: p.V117V or p.S146X in alternate transcript) demonstrated increased proliferation over six matched controls. **P < 0.005 and ***P < 0.0005. Data represent means SEM of three biological replicates using three technical replicates each. (B) The same five H3F3A/B patient fibroblasts and six controls show no major differences in cell viability. The data represent the means SEM of four biological replicates using two technical replicates each. (C) Cell cycle analysis showed differences in the S (P = 0.0127) and G2 (P = 0.0338) phase in the same five patient cell line compared to the six control fibroblast lines. Data represent the means SEM of four biological replicates using two technical replicates each.

A dominant zebrafish model (p.D123N) derived from a forward genetic screen has been previously reported with craniofacial abnormalities, which were replicated in our patient cohort (Fig. 6A) (18). This heterozygous missense variant replicates the dominant inheritance observed in humans and is only two amino acids away from a mutation identified in an affected patient (p.Q125R). Further investigation of this model also reveals a defect in foxd3-positive neural crestderived glia, as well as melanocytes and xanthophores (Fig. 6, B to D.) The loss of glial cells may relate to the hypomyelination phenotype that is noted on the brain MRIs of over one-third of the H3.3 cohort as glial cells are the cell type responsible for myelination.

(A) Ventral whole-mount views of larval zebrafish heads at 5 dpf stained with Alcian Blue. Homozygous h3f3adb1092 mutants display complete loss of neural crestderived jaw cartilages (n = 10/10). (B to D) In situ hybridization of zebrafish embryos for markers of glia (foxd3; 24 hpf), melanocytes (dct; 27 hpf), and xanthophores (xdh; 27 hpf). Homozygous h3f3adb1092 mutants injected at the one-cell stage with a control mCherry RNA show partial reductions in cranial glia (n = 5), melanocytes (n = 4), and xanthophores (n = 3), while those injected with dominant-negative H3f3a RNA to further reduced H3.3A function show complete loss of melanocytes (n = 5) and severe reductions of glia (n = 6) and xanthophores (n = 4) throughout cranial and trunk regions.

The discovery of missense mutations in H3.3 that cause a neurodevelopmental disorder, but not cancer, has profound implications for future research in histone biology. Until now, H3.3 mutations have only been directly linked to cancer (6). These specific mutations that cause a neurodevelopmental phenotype are distinct from the ones that cause cancer. The cancer mutations are mostly in lysines in the histone tail, while the only lysine mutation in our cohort is p.K36E. When this lysine-36 is mutated in cancer, it is mutated to methionine and not glutamate (19). The patient with the p.K36E mutation was 32 years old when he was last evaluated and still had no signs of cancer, suggesting that the p.K36E mutation does not lead to a strongly increased risk of malignancy. The only other variant in our cohort that is similar to a cancer-linked variant is the p.G34V mutation in H3F3B. This p.G34V variant in H3F3A has been shown to cause cancer only when combined with mutations in ATRX/DAXX (ATRX Chromatin Remodeler/Death Domain Associated Protein) and TP53 (TAR-DNA binding protein-43) (19). Understanding why the somatic p.G34V variant causes cancer, but germline variants cause a neurodevelopmental phenotype, is currently unknown and requires further study.

Notably, although the mutations are spread throughout the coding sequence, they all converge on a similar phenotype. Each mutation affects different specific interactions but converge on the same phenotype. This suggests that the phenotype is due to dysregulation of H3.3 in general and not limited to a single mechanism. Molecular modeling revealed that mutations in the histone core likely affect nucleosome stability, while the mutations in the tail affect various protein-protein interactions. In addition to molecular modeling data, previous work in other species such as yeast can provide insights into the pathogenic mechanism of these variants. Of particular interest, two of the five amino acids that differentiate H3.3 from canonical H3 (p.S31 and p.G90) are mutated in our patient cohort. Both p.S31 and p.G90 are essential for proper recognition of H3.3 by other proteins. Mutagenic analysis in yeast shows that mutations at p.G90 prevent H3.3-specific chaperones DAXX and UBN1 (Ubinuclein 1) from binding (20). The serine at position 31 is required for recognition of H3.3 by ZMYND11 (21). Mutations in ZMYND11 cause an autosomal dominant neurodevelopmental phenotype similar to that seen in our patient cohort, including hypotonia, seizures, dysmorphic facial features, and developmental delay (22). A second mutation in our patient cohort, p.G34V, has also been shown to disrupt ZMYND11 binding to H3.3 (21). Other variants may disrupt histone octamer formation, nucleosome sliding, and chaperone binding based on mutagenic analysis of both H3 and H3.3 in model organisms (2325). We hypothesized that additional missense mutations in our cohort induce epigenetic dysregulation of histone PTMs. These histones PTMs within the nucleosome affect chromatin state, mitotic initiation, protein-chromatin interactions, and gene expression (2630). Specific PTMs of unincorporated histones also mediate chaperone recognition before incorporation into the nucleosome (31).

The fact that all of these mutations are heterozygous is particularly noteworthy. Since there are two genes that produce H3.3, a heterozygous mutation in one of them means that 75% of the alleles are WT. A missense mutation in only 25% of the alleles is sufficient to cause global developmental delay, hypomyelination, cortical atrophy, and craniofacial anomalies. H3F3A and H3F3B are not expressed at the same levels so the amount of mutant protein could be more or less than 25% in any individual patient or tissue at any particular time; however, we observe the same phenotype regardless of whether the mutation is in H3F3A or H3F3B so a higher expression level from one of the genes cannot explain the severity of the phenotype. The fact that a single missense mutation in one allele causes such a severe phenotype strongly supports the importance of tight regulation of histones and histone PTMs. Furthermore, since our studies showed that the changes in the PTMs are in cis on the mutant H3.3 and not in trans on the WT H3.3 in the same nucleosome as is observed in the cancer causing mutations, the severity of the phenotype cannot be explained by a global dysregulation of PTMs.

Although the exact mechanism of the cellular pathology in these patients is unclear, H3.3 is vital for normal neurologic functioning. A recent study showed that H3.3 begins to replace H3.1 and H3.2 in postnatal mouse and human brains in a time-dependent manner and displaces these canonical H3 variants almost completely in adulthood. The important role of H3.3 over time may explain the unique neurodegenerative phenotype, as mice with decreased H3.3 expression in the hippocampus have impaired long-term memory (32). Humans with major depressive disorder have increased percentages of H3.3 in the nucleus accumbens, which is modulated by antidepressant therapy (33). This suggests that H3.3 modulators may represent potential targeted therapies for H3.3-related disorders and perhaps associated neuropsychiatric conditions in the general population. Future studies in patient-derived induced pluripotent stem cell neural cell types may further elucidate the underlying pathology.

Although these are the first germline variants associated with histone H3, germline variants in histones H1 and H4 with similar features have been reported. The overgrowth and neurodevelopmental delay associated with Rahman syndrome (MIM 617537) are caused by truncating variants in H1 Histone Family, Member E (HIST1H1E). (34) Recently, two specific germline variants in histone H4, which caused delayed growth and neurodevelopment, have been described in two families (35). In addition, there are many neurodevelopmental disorders associated with the histone lysine methylases and demethylases. These histone-related disorders provide a unique window into the role of histones in the control of development and growth.

In conclusion, we show here that heterozygous de novo missense variants in H3F3A and H3F3B, coding for H3.3, are associated with a previously undescribed phenotype of developmental delay, neurodegeneration, epilepsy, facial dysmorphism, and congenital anomalies. The functional effects of these mutations appear to be different from those that are well-studied in cancer and may offer a target for therapy for these and other patients.

The Institutional Review Boards of Columbia University, the University of Michigan, Childrens Hospital of Eastern Ontario, University Medical Center Hamburg-Eppendorf, and the Childrens Hospital of Philadelphia approved this study. Informed consent was obtained from all individual participants included in the study. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Genomic DNA was extracted from whole blood from the affected children and their parents. Exome or genome sequencing was performed with a variety of standard capture kits and the general assertion criteria for variant classification following ACMGG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) guidelines (36). There were no other variants in these patients that survived filtration and analysis using either dominant or recessive models and could explain the phenotypes.

Six healthy control cells lines that were matched to available patient cells for passage number, age, and sex were obtained from the Coriell Institute for Medical Research tissue bank. All these fibroblast samples were derived from skin biopsies performed either on the arm or on the leg of the patient. Only a portion of the patients who participated in our study agreed to donate cellular material, and the patient mutations that were analyzed reflect the sum of the viable donations.

Histones were purified in acid as previously described by Karch et al. (37). Acid-extracted histones (15 to 25 g) were resuspended in 100 mM ammonium bicarbonate (pH 8), derivatized using propionic anhydride, and digested with trypsin as previously described (37). The resulting histone peptides were desalted using the C18 Stage Tips, dried using a centrifugal evaporator, and reconstituted using 0.1% formic acid in preparation for nanoLC-MS analysis.

Nano-LC was performed using the Thermo Fisher Scientific Easy nLC 1000 System equipped with a 75 m by 20 cm in-house packed column using Reprosil-Pur C18-AQ (3 m; Maisch GmbH, Germany). Buffer A was 0.1% formic acid, and buffer B was 0.1% formic acid in 100% acetonitrile. Peptides were resolved using a two-step gradient from 0 to 26% B over 45 min and then from 26 to 98% B over 10 min at a flow rate of 300 nl/min. The high-performance LC was coupled online to an Orbitrap Elite mass spectrometer operating in the positive mode using a Nanospray Flex ion source (Thermo Fisher Scientific) at 2.40 kV. MS was performed using data-independent acquisition (DIA) as previously described with slight modifications (37). Briefly, two full MS scans [mass/charge ratio (m/z), 300 to 100) were acquired in the Orbitrap with a resolution of 120,000 (at 200 m/z) every eight DIA MS/MS events using isolation windows of 50 m/z each (e.g., 300 to 350, 350 to 400 650 to 700). The full MS scan is performed twice within the same duty cycle to allow for a more resolved definition of the precursor peak profile. MS/MS events were acquired in the ion trap operating in normal mode. Fragmentation was performed using collision-induced dissociation in the ion trap mass analyzer with a normalized collision energy of 35. Automatic gain control (AGC) target and maximum injection time were 10 106 and 50 ms for the full MS scan and 10 104 and 150 ms for the MS/MS scan, respectively.

Data were searched using EpiProfile. The peptide relative ratio was calculated using the total area under the extracted ion chromatograms of all peptides with the same amino acid sequence (including all of its modified forms) as 100%. For isobaric peptides, the relative ratio of two isobaric forms was estimated by averaging the ratio for each fragment ion with different mass between the two species. Two to three biological replicates were analyzed per condition, and the relative abundance of each peptide modification was averaged across the runs.

Isolated histones were separated on a 4 to 12% NuPAGE bis-tris gel and transferred to a 0.2-m nitrocellulose blotting membrane. Membranes were blocked in TBS-T [50 mM tris-HCl (pH 7.5), 150 mM NaCl, and 0.1% Tween 20] containing 5% milk powder and probed for H3.3 (Thermo Fisher Scientific, MA5-24667; 1:5000), H3 (Abcam, ab1791; 1:5000), and H4 (Abcam, ab7311; 1:5000) primary antibodies diluted in TBS-T containing 5% milk powder. This was followed by anti-rabbit horseradish peroxidase (Abcam, ab99697; 1:10,000) and visualized using enhanced chemiluminesence prime Western blotting detection chemiluminescent reagent.

RNA was extracted using the RNeasy Mini Kit (QIAGEN) on the six samples at the same time. Extracted RNA samples underwent quality control assessment using Bioanalyzer (Agilent, Santa Clara, CA, USA) and were quantified using NanoDrop from NanoDrop Technologies (Wilmington, DE, USA). RNA libraries were prepared using the Illumina TruSeq RNA sample prep V2 with ribosomal RNA depletion and were sequenced using HiSeq 2500 sequencer (Illumina Inc., San Diego, CA, USA) at the Center for Applied Genomics at the Childrens Hospital of Philadelphia per standard protocols (paired-end 100 base pairs). The RNA-seq data were aligned on the hg19 reference genome using STAR (www.encodeproject.org/software/star/) and processed using Cufflinks (http://cole-trapnell-lab.github.io/cufflinks/). For each gene, we compared the expression levels between cases and controls. A gene was considered differentially expressed if the P value is less than 0.05 and fragments per kilobase of transcript per million mapped reads has at least twofold change. To identify overrepresented functional categories among genes that are differentially expressed, we performed annotation analysis using the David Functional Annotation Resource (https://david.ncifcrf.gov/). Multiple testing was adjusted using the Benjamini-Hochberg approach, and enrichment was declared if the adjusted P value is less than 0.05.

Cellular proliferation was assayed with five patients and six control fibroblast cell lines; they were plated at 3 104 cells per well and then were manually counted at baseline, 24, 48, 72, and 96 hours. Then, the means SEM of three biological replicates using three technical replicates each were analyzed. Cell viability was analyzed with three patients and three control fibroblast cell lines; the cells were plated and grown until ~80% confluent. Then, they were stained for annexin V/propidium iodide (PI), and fluorescence-activated cell sorting (FACS) was performed on Accuri C6 (BD Biosciences). Then, the means SEM of four biological replicates using two technical replicates each were analyzed. Cell cycle analysis was performed with three patients and three control fibroblast cell lines; the cells were plated and grown until ~80% confluent. They were then stained for PI, and FACS was performed on Calibur and analyzed by FlowJo. Then, the means SEM of four biological replicates using two technical replicates each were analyzed.

All zebrafish experiments were approved by the University of Southern California Institutional Animal Care and Use Committee (protocol #20258). h3f3adb1092 mutants were genotyped, and control mCherry or dominant-negative D123N H3f3a mRNAs were prepared and injected at 900 ng/l into one-cell stage embryos as described (18). Acid-free cartilage staining with Alcian Blue was performed as described (38). In situ hybridization was performed with the probes and procedures described in (18). Images were captured on a Leica DM2500 compound microscope.

For each H3.3 variant location, we analyzed its pattern of interatomic contacts (see below) using experimental structural information. The list of known structures was retrieved from the UniProt record of H3.3 (P84243). In all cases, the structure of H3.3 was incomplete, that is, only a fragment in complex with other proteins is described. For each variant, we identified the Protein Data Bank (PDB) entries that provided information about its location. We provide a table of the PDB files used in table S5.

For each variant, we computed the network of interatomic interactions of the native residue. This network was obtained following a simple protocol: (i) retrieve the corresponding PDB, (ii) compute the network of interactions for all the protein residues using Ring, (iii) extract the interaction data corresponding to the native residue, and (iv) organize these interaction data into three groups [intramonomer (within the same H3.3 monomer), intermonomer (between H3.3 monomer and other proteins), and H3.3-DNA] (39). Intramonomer interactions were only kept when the atoms involved came from residue pairs (i,j) separated by more than two residues in sequence, i.e., |i j| > 2. Ring computations were executed with default parameters, except for interaction type, which was set to all. H3.3-DNA contacts were only included if their distance was lower than 5.5 .

Acknowledgments: We thank the families for contribution. We also thank J. F. Deleuze, A. Boland, and V. Meyer from the CNRGH for genome sequencing and data primary analysis. Funding: Funding was provided by the French Foundation for Rare Diseases (Fondation maladies rares). This work was also supported in part by a grant from the from SFARI (to W.K.C.), JPB Foundation (to W.K.C.), and the Morton S. and Henrietta K. Sellner Professorship in Human Genetics (to J.W.I.), as well as an NIDDK T35 training grant (T35DK093430) (to E.F.J.). E.J.B. was supported by a K12 training grant (K12HD043245-14) and the Roberts Collaborative. D.M. was supported by a T32 training grant (T32GM008275). Funding from NIH grants GM110174 and CA196539 to B.G. is acknowledged. This research was funded in part by the Estonian Science Foundation grant PUT0355 and PRG471. Analysis for one patient was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung, and Blood Institute grant UM1 HG008900 to D. MacArthur and H. Rehm. Support also provided by NIH T32 HD07466 (to M.H.W.), Alabama Genomic Health Initiative F170303004 through University of Alabama at Birmingham IRB (to A.C.H., J.D., and M.T.) The Toronto-based authors (to G.C., M.S.M., and D.C.) acknowledge support from the Centre for Genetic Medicine, The Centre for Applied Genomics, and the Norman Saunders Complex Care Initiative. The Care4Rare Canada Consortium is funded by Genome Canada, the Canadian Institutes of Health Research, the Ontario Genomics Institute, Ontario Research Fund, Genome Quebec, and Childrens Hospital of Eastern Ontario Foundation. This work was also supported by Dipartimenti di Eccellenza 20182022 Project code D15D18000410001 to A.B. and Fondazione Bambino Ges (Vite Coraggiose) and Italian Ministry of Health (CCR-2017-23669081) to M.T. Author contributions: A.B., A.C.H., A.J.Y., A.L., A.P.A.S., A.Z., B.F., C.F., C.G.S.P., C.T.R.M.S., D.H., D.N., E.Bri., E.Bro., E.V., F.C.R., H.K., G.B.F., G.G., J.A.M.-A., J.C.P., J.M.T., J.Ne., J.No., J.S.S., K.E.S., K.M., K.T., K.Wie., K.Wil., L.B., L.U., L.W.L., M.B., M.G.M., M.I.V.A., M.S., M.Ta., M.Th., N.H.P., N.L., R.J.L., R.R.L., S.A.S.V., S.F.N., S.J.C.S., S.M.-A., S.S.C., T.H., T.P., W.K.C., E.J.B., M.J.Lyo., M.J.Lar., W.C., E.She., E.Sel., K.J.W., A.W., G.M.S.M., N.P.-H., J.v.d.K., T.G., John Dean, J.Den., Joy Dean, A.R., H.P.C., M.C.W., L.M., C.N., A.A., D.Les., T.K., J.Win., J.Wan., C.B.C., A.Vol., A.Van., E.F.J., J.L.S., J.W.I., A.P., S.L., H.D., J.H., H.R., B.K., O.S., S.O., S.M., K.Ret., K.Rad., K.., P.I., A.M.I., G.C., M.S.M., D.Chi., D.Car., M.M.W., and E.Z. contributed to the clinical evaluation of the affected individuals. R.B., J.A.L., B.R., Z.P., M.C., R.S., D.Les., M.W., K.Ret., K.Rad., T.M.S., K.G.M., R.G., K.R., C.M., K.L.H., B.C., S.Bez., S.Bar., T.B., S.K., R.R., M.H.W., K.D.K., Care4Rare Canada Consortium, CAUSES Study, DDD Study, and Undiagnosed Disease Program contributed to the molecular evaluation of the affected individuals. E.J.B., D.Les., H.H.H., M.E.M., B.G., D.M., K.J., Z.-F.Y., P.L., C.S., J.G.C., X.d.l.C., N.P., S.G.C., K.Wil., and D.Li contributed the functional evaluation of the variants found in the affected individuals. Competing interests: K.R. and K.M. are employees of GeneDx. W.K.C. and M.C. were employees of GeneDx. The authors declare that they have no other competing interests. Data and materials availability: Patient variants will be available in ClinVar. All patient materials may be obtained through a material transfer agreement. All other data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Go here to read the rest:
Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients...

When applying genetics to the study of COVID-19, scientists are learning a lot. Our DNA codes for proteins, some of which are required for SARS-CoV-2 to interact with and infect a host cell, others that are implicated in the downstream effects of viral infection, such as inflammatory responses. But how do scientists choose which genes to study?A new study by Dr Thomas Stoeger, a postdoc at North Western University, suggests there is a historical bias involved; scientists are studying human genes that have already been heavily investigated, independent of COVID-19.

In this installment of Teach Me in 10, Stoeger expands on the key points of this study and the implications of bias in scientific research.

Full research publication: Meta-Research: COVID-19 research risks ignoring important host genes due to pre-established research patterns.

For more Teach Me in 10 videos, check out our hub page.

Are you a Facebook user? Like the Teach Me in 10 Facebook page to engage and network with the video audience.

See original here:
Teach Me in 10 Why COVID-19 Genetics Research May Be Biased With Dr Thomas Stoeger - Technology Networks

Bathinda: Central University of Punjab, Bathinda (CUPB) under the patronage of Vice Chancellor Prof. Raghavendra P. Tiwari organised a Webinar on Population Genomics and Public Health. On this occasion, Dr. Kumarswamy Thangraj, Director, Centre for Fingerprinting and Diagnostics (CDFD), Hyderabad was the keynote speaker.

The programme commenced with the Welcome Address by Prof. Anjana Munshi, Dean Research, where she put a light on the topic of the webinar. While introducing the keynote speaker, she mentioned that Dr. Kumarswamy Thangraj is an acclaimed senior geneticist of India who is known for his contributions in the field of population and medical genetics.

In his keynote address, Dr. Kumarswamy Thangraj talked about how population genomics, the study of evolution of humans, and the genetics of modern human helps in understanding the human health. While putting a light on the evolution of human beings, he mentioned that earlier human species diverged from their homogenates like Chimpanzee about 7.5 Million Years Ago.(MYA). He also discussed different stages of evolution of human beings including Hominidae, Ardipithecus Ramidus, Australopithecus Afarensis, Homo Hebilis, Homo Erectus, Homo Heidelbergensis, Homo Sapiens and pointed out that during these stages the human brain has developed over a period of time and its size has increased as compared to the predecessors. He stated that Neanderthals were the early archaic human with larger brain size who emerged around 200 thousand years ago but they were replaced by early modern humans.

Dr. Kumarswamy Thangraj informed that several geological tools including the draught of Malwai Lake have indicated that modern humans originated in Africa and migrated to different parts of the world. He also shared that the recent studies have shown that enigmatic tribal populations of Andaman and Nicobar Islands are the first modern humans who migrated out of Africa through the Southern Coastal Route about 65,000 years ago.

He stated that India is a genetic hotspot and there are more than 4500 anthropologically well-defined population groups and genetic identity of different ethnic groups helps in identifying the health status of that population. He added that due to the practice of endogamy, the disease pattern is restricted to that particular population. Dr. Kumarswamy Thangraj asserted that IBD Scores (Identity by dissent scores) helps the researchers to find the level of identical DNA and know about their ancestors of several decades back. Further, the level of similarity of gene mutation pattern helps in identifying the health risk level of that ethnic group. During this webinar, various genetic diseases including mitochondrial diseases were discussed and it was suggested that a community genetic testing programme helps in identifying the health risk factor of a population.

Prof. R.K. Wusirika, Dean Incharge Academics, appreciated the keynote speaker for scholastic discourse. Towards the end, Dr. Sandeep Singh delivered the formal vote of thanks. This Webinar was attended by faculty and students of the university.

Continued here:
Central University of Punjab organized Webinar on Population Genomics and Public Health' - India Education Diary

Gitanjali Rao occupied the top spot on the trends list on Friday after TIME Magazine named her as its first-ever Kid of the Year 2020. The 15-year-old Indian-American is an aspiring scientist and inventor, and she was among 5,000 nominees, pitted against each other for the distinction.

We will tell you more about Gitanjali. But, before that, do you know Gitanjali appeared as a guest speaker on the second season of TED Talks India: Nayi Baat with Shah Rukh Khan in 2019? On the show, Gitanjali discussed her passion for science and also demonstrated experiments in front of Shah Rukh Khan.

The superstar was absolutely impressed with the "simply incredible" Gitanjali and applauded her after she said that she intends to make the world a better place.

Here are 10 things that Gitanjali Rao told Shah Rukh Khan on TED Talks India: Nayi Baat in November last year:

HOW ARE SCIENTISTS DIFFERENT FROM SUPERHEROES?

"In our minds, superheroes can jump tall buildings, have technology gadgets. Have superpowers such as flying and robotic hands. But what do they all have in common? The ability to save lives and the magical thing is that they show up exactly at the right time to save lives. If superheroes were real, we would give them all of the support in the world. Wouldn't we? Well, how are real, breathing, living scientists different from the superheroes in movies and comics? No matter where they are, scientists come up with solutions to help people."

I WANT TO BE A SCIENTIST SUPERHERO

"I love science and I want to be a scientist superhero, solving real world problems and saving lives."

IT'S NEVER TOO EARLY TO START MAKING A DIFFERENCE

"I like to think of solutions every time I see a problem in the society. It's never too early to start making a difference and I can prove of that by sharing some of my journey towards innovation."

WHAT IS TETHYS?

"The health effects of lead in water ranges from anywhere. From just headaches and nausea to possible seizures and even death. I invented my device Tethys to detect lead levels in water. By dipping it into the water sample, it can speedily detect the lead content, how people take preventive measures such as switching to a filtered-water source, and maybe even save lives."

PROTOTYPE BASED ON HUMAN GENETICS

"I am currently working on another prototype that is based on human genetics and can detect the growing problem of prescription drug addiction. I have chosen to develop an easy to use portable and efficient device that physicians can use to tell if their patients are at the onset of addiction."

FORTUNATE TO HAVE INCREDIBLE MENTORS

"I am fortunate to have some incredible mentors who believe in me, inspire me and mentors whom I have learn from, and will continue to learn from."

I AM LEARNING EVERY SINGLE DAY

"I am learning every single day. Learning about the problems around us. Learning about new technology options. Learning about ways to solve them, and how me, and other young innovators like me, can come up with solutions."

I AM JUST 13 BUT THAT'S GOOD NEWS

"I may only be 13, but that's good news because hopefully, I have many years ahead of me to be a scientist, to solve problems, to save lives, and to make the world a better place for me, and for children who haven't been born yet."

WHAT IS THE PURPOSE OF SCIENCE?

"I believe that the purpose of science is to make a difference. We can all do our part in society by mentoring, volunteering and raising funds."

WE CAN ALL BE SUPERHEROES

"I don't think there should be an age barrier to solving problems. I hope that with the right focus and approach to continuous learning, we can all be superheroes, saving lives."

WHO IS GITANJALI RAO?

Based in Colorado, US, Gitanjali Rao is a scientist, who aspires to study genetics and epidemiology at Massachusetts Institute of Technology. She won the Discovery Education 3M Young Scientist Challenge in 2017 and was also recognised as Forbes 30 U 30 for her innovations. In September 2018, Gitanjali Rao was awarded the United States Environmental Protection Agency President's Environmental Youth Award.

ALSO READ: Indian American Gitanjali Rao, 15, named first ever TIME Kid of the Year 2020

ALSO READ: Myanmar monk creates refuge for snakes at monastery. Viral pics

Go here to see the original:
10 things Kid Of The Year Gitanjali Rao told Shah Rukh Khan on TED Talks in 2019 - India Today

Researchers from Germanys Max Planck Institute of Molecular Cell Biology and Genetics in Germany and Japans Central Institute for Experimental Animals introduced a specifically human gene,ARHGAP11B, into the fetus of a common marmoset monkey, causing the enlargement of its brains neocortex. The scientistsreported their findings in Science.

The neocortex is the newest part of the brain to evolve. Its in the nameneo meaning new, and cortex meaning, well, the bark of a tree. This outer shell makes up more than 75 percent of the human brain and is responsible for many of the perks and quirks that make us uniquely human, including reasoning and complex language.

The scientists call these human-monkey hybrids transgenic non-human primates, which may be enough to ring the alarm of any doomsdayer. It certainly raises a lot of ethical questions when doing experiments on primates, let alone when introducing human genes into other animals.

For this reason, the researchers limited their study to monkey fetuses, which were taken out by C-section after growing for 100 days. Allowing the experiment to go past the fetal phase and let the human gene-carrying monkeys to be born would beirresponsible and unethical, study coauthor Wieland Huttner said in the press release.

Read the original post

Here is the original post:
Planet of the Apes redux? Human brain gene inserted into monkey fetuses enlarged their brains, raising ethical concerns - Genetic Literacy Project